Recombinant DNA Molecules for Human Fibroblast Interferon Production
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing human fibroblast interferon (HuIFN-β) are inefficient, resulting in low yields and high costs, and existing recombinant DNA technology struggles to accurately clone and express the gene sequence for HuIFN-β, leading to difficulties in producing active polypeptides.
Innovation Solution
The development of DNA sequences and recombinant DNA molecules that specifically code for human fibroblast interferon-like polypeptides, allowing for their production in appropriate hosts, enabling the isolation and expression of immunologically and biologically active HuIFN-β polypeptides for use in antiviral, antitumor, and anticancer applications.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If traditional methods are used to produce human fibroblast interferon, then production costs are high and yields are low, but the process is simpler to implement
Solution Approach 1:
The patent uses recombinant DNA technology as an intermediary system, inserting the HuIFN-β gene into host cells (such as E. coli or mammalian cells) to act as biological factories. This mediator system enables high-yield production of interferon through genetic expression rather than traditional extraction methods, resolving the contradiction between productivity and manufacturing complexity.
Solution Approach 2:
The invention changes the fundamental production parameter from chemical/biological extraction to genetic expression. By transforming the production mechanism through recombinant DNA technology, the system achieves higher yields while the standardized genetic engineering protocols actually reduce long-term manufacturing complexity despite initial setup requirements.
2Manufacturing precision
If existing recombinant DNA technology is used to clone HuIFN-β gene, then the cloning process is simplified, but the accuracy of cloning and expression of active polypeptides is poor
Solution Approach 1:
The patent applies preliminary actions by carefully designing and optimizing the recombinant DNA construction process before actual expression. This includes selecting appropriate restriction enzymes, designing proper cloning sites, and preparing host cells in advance with necessary regulatory elements, thereby ensuring high accuracy of cloning and expression while managing system complexity through systematic preparation.
Solution Approach 2:
The invention replaces mechanical/experimental trial-and-error cloning methods with a more precise genetic engineering system. By using specifically designed restriction sites, ligases, and transformation protocols, the system achieves accurate cloning and expression of functional HuIFN-β polypeptides, substituting less precise mechanical procedures with controlled biochemical processes.
3Quantity of substance
If more HuIFN-β polypeptides are produced for medical applications, then therapeutic availability is improved, but production costs and technical difficulties increase
Solution Approach 1:
The patent implements self-service by enabling host cells to automatically produce HuIFN-β polypeptides through their own cellular machinery once the gene is inserted. The recombinant cells serve themselves as production factories, continuously synthesizing interferon through natural transcription and translation processes, thereby achieving large quantities without proportionally increasing production difficulty.
Solution Approach 2:
The invention achieves universality by using standardized recombinant DNA vectors and host cell systems that can produce multiple therapeutic proteins. The same basic platform technology can be applied to produce different cytokines and proteins, spreading development costs and technical expertise across multiple applications, thereby reducing the difficulty of producing large quantities of HuIFN-β.
Data Source
AI summary
DNA sequences, recombinant DNA molecules and hosts transformed with them which produce polypeptides displaying a biological or immunological activity of human fibroblast interferon, the genes coding for these polypeptides and methods of making and using these DNA sequences, molecules, hosts, genes and polypeptides. The DNA sequences are characterized by in that they code for a polypeptide displaying a biological or immunological activity of human fibroblast interferon. In appropriate hosts these DNA sequences and recombinant DNA molecules permit the production and identification of genes and polypeptides displaying a biological or immunological activity of human fibroblast interferon and their use in antiviral and antitumor or anitcancer agents.